Six months ago, disturbing liver biopsies suggesting some patients in an FDA Phase 2b study of CymaBay Therapeutics (CBAY) suffered inflamed and destroyed liver cells forced the company to suspend nonalcoholic steatohepatitis (NASH) treatment trials of its seladelpar liver treatment drug — and cost CymaBay stock 75% of its market cap. Six months later, a new study just showed no evidence that seladelpar causes liver damage, giving CymaBay the all-clear to proceed with its trials, and more than doubling the stock’s share price on Tuesday.Analysts rushed to hail the results, and as of today, every one of the six analysts …read more
Source:: Yahoo Finance
